Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IASLC TTLC 2022 | Updates in the SCLC treatment landscape

Triparna Sen • 21 Feb 2022
IASLC TTLC 2022
Lung Cancer Small Cell Lung Cancer

Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses upcoming small cell lung cancer (SCLC) trials assessing novel targets, including lysine-specific histone demethylase 1A (LSD1) inhibitors, enhancer of zeste homolog 1/2 (EZH1/2) inhibitors and DNA damage response inhibitors. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).

More from Triparna Sen

3:33
Molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer
Triparna Sen • 8 Aug 2022
2:11
Combination of WEE1 inhibition and immunotherapy provides promising preclinical data for SCLC
Triparna Sen • 21 Mar 2022
2:15
DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC
Triparna Sen • 21 Mar 2022
2:56
Current therapeutic landscape for small-cell lung cancer
Triparna Sen • 21 Mar 2022

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals